LitAlert ~~ GeneLit.com

    • Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    • Galmor L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, Zippel D, Laitman Y, Friedman E.
    • Breast Cancer Res Treat. 2020 Sep 30. doi: 10.1007/s10549-020-05949-z. Epub ahead of print.
    • Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, McCuaig JM, Karlan BY, Eisen A, Tung N, Bordeleau L, Senter L, Eng C, Couch F, Fruscio R, Weitzel JN, Olopade O, Singer CF, Pal T, Foulkes WD, Neuhausen SL, Sun P, Lubinski J, Narod SA, the Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2020 Sep 30:S0090-8258(20)33947-0. doi: 10.1016/j.ygyno.2020.09.037. Epub ahead of print.
    • Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations.
    • Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N, Mauer C, Pirzadeh-Miller S, Gao A, Li H, Unni N, Syed S.
    • Ann Surg Oncol. 2020 Sep 29. doi: 10.1245/s10434-020-09158-2. Epub ahead of print.
    • Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
    • Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S, Cuningham K, Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A.
    • Hered Cancer Clin Pract. 2020 Sep 29;18:20. doi: 10.1186/s13053-020-00152-z.